Sheila Ramirez Rodriguez, MD
Endocrinology, Diabetes & Metabolism · Martinsburg, WVNPI 1740415405
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,593 of the $4,734 with a category attached, or 75.9%. 27 manufacturers reported payments, led by Medtronic at 35.7% of the total. 2025 is the largest year on record at $1,879, 2.4 times the $790 reported in 2019.
Across 178 payments — averaging $26.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Lilly USA, LLC$835
- Novo Nordisk$522
- AstraZeneca$420
- AbbVie$159
- Sanofi-aventis U.S. LLC$150
- plus $960 from 21 others
What the payments were for
- Travel & lodging$1,10423%
- Food & beverage$3,59376%
- Education$371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 22 | $1,688 |
| Lilly USA, LLC | 42 | $835 |
| Novo Nordisk | 32 | $522 |
| AstraZeneca | 14 | $420 |
| AbbVie | 9 | $159 |
| Sanofi-aventis U.S. LLC | 8 | $150 |
| Dexcom, Inc. | 6 | $135 |
| Insulet Corporation | 7 | $131 |
| Abbott | 6 | $121 |
| Amgen | 6 | $96 |
| IBSA Pharma Inc. | 4 | $69 |
| Johnson & Johnson | 3 | $52 |
| Boehringer Ingelheim | 3 | $47 |
| Tandem Diabetes Care, Inc. | 2 | $36 |
| Bayer | 2 | $35 |
| Currax Pharmaceuticals LLC | 1 | $25 |
| Zealand Pharma US, Inc. | 1 | $25 |
| Averitas Pharma Inc. | 1 | $25 |
| Ascensia Diabetes Care US Inc. | 1 | $23 |
| Novartis | 1 | $21 |
| Alfasigma USA, Inc. | 1 | $21 |
| Radius Health, Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $19 |
| Lifescan, Inc. | 1 | $19 |
| Sequel Med Tech, LLC | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,160
- FARXIGA$100
How this compares
$4,734 in reported general payments places this provider in the 70th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
See all endocrinology, diabetes & metabolism providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 291 | $520,101 |
| OzempicSemaglutide | 274 | $476,649 |
| JardianceEmpagliflozin | 306 | $348,872 |
| Tresiba Flextouch U-200Insulin Degludec | 131 | $169,553 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 116 | $129,343 |
| FarxigaDapagliflozin Propanediol | 98 | $100,817 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 180 | $98,884 |
| TrulicityDulaglutide | 66 | $96,222 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 42 | $69,177 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 29 | $60,049 |
| RybelsusSemaglutide | 41 | $50,724 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 41 | $49,317 |
| JanuviaSitagliptin Phosphate | 48 | $45,815 |
| Tresiba Flextouch U-100Insulin Degludec | 74 | $45,812 |
| TradjentaLinagliptin | 61 | $44,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $835 | $623,282372 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog | $522 | $609,810390 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $47 | $409,093391 claims |
| AstraZenecaFarxiga | $420 | $100,81798 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $150 | $60,04929 claims |
| Johnson & JohnsonInvokana | $52 | $25,26123 claims |
| AbbVieSynthroid | $159 | $22,859266 claims |
| BayerKerendia | $35 | $19,06520 claims |
| IBSA Pharma Inc.Tirosint | $69 | $8,83649 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
Other endocrinology, diabetes & metabolism in Martinsburg
- Zachary KistkaMartinsburg$120K
- Philip RyanMartinsburg$35K
- James FieldMartinsburg$930
- Emma Morton-EgglestonMartinsburg$206
- Daniel MaciasHuntington$686K
- Jeremy SouleBridgeport$109K
- John EplingBridgeport$28K
- Greta GuyerSouth Charleston$22K
- Arlene FederWeirton$20K
- Ziad KahwashSouth Charleston$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.